The effects of a growth hormone-releasing hormone antagonist and a gastrin-releasing peptide antagonist on intimal hyperplasia of the carotid artery after balloon injury in a diabetic rat model☆
This research was partially presented as an abstract at the American College of Cardiology 2013 Scientific Sessions with publication as a supplement in the Journal of the American College of Cardiology: (J Am Coll Cardiol. 2013; 61 (10_S): doi:10.1016/S0735-1097(1361178)) however it has not been published in any other form and is being considered solely by Artery Research.
- DOI
- 10.1016/j.artres.2017.06.006How to use a DOI?
- Keywords
- Neointimal hyperplasia; Growth hormone-releasing hormone antagonist; Gastrin-releasing peptide antagonist; Arterial restenosis; Diabetes mellitus
- Abstract
Introduction: Arterial restenosis after angioplasty/stenting has hindered coronary artery disease treatment, especially in diabetics. We theorized that gastrin-releasing peptide (GRP) antagonists and growth hormone-releasing hormone (GHRH) antagonists might decrease neointimal hyperplasia and restenosis in diabetic rats after common carotid arterial balloon injury.
Methods: Two separate experiments were conducted to test the effects of a GRP antagonist (RC-3095) and a GHRH antagonist (MZ-4-71) on vascular smooth muscle (VSM) growth. In a preliminary in vitro experiment non-injured human aortic vascular smooth muscle (VSM) proliferation was compared between growth media and control. In a second in vivo experiment, intimal and medial area, intima/media ratio (IM) and percent stenosis were compared between injured carotid arteries in twelve Zucker type II obese rats treated with subcutaneously injected RC-3095, MZ-4-71, or control media.
Results: In the in vitro experiment, decreased VSM cell growth was observed in GRP antagonist (p < 0.05) and GHRH antagonist groups (p < 0.05) compared to the control group. In the in vivo experiment, the GRP antagonist group had a decreased IM ratio (1.63 ± 0.41, p < 0.05) and an increased area of stenosis (98.78% ± 1.48 p = NS) compared to control (2.38 ± 1.09) while the GHRH antagonist group had decreased IM ratio (1.33 ± 0.58 SD, p < 0.05) and percent area of stenosis (78.84% ± 24.97, p < 0.05) compared to control (2.38 ± 1.09).
Conclusions: The significant decrease in both IM ratio and percent area of stenosis in the GHRH antagonist group supports the hypothesis that this peptide may reduce neointimal hyperplasia and restenosis.
- Copyright
- © 2017 Association for Research into Arterial Structure and Physiology. Published by Elsevier B.V. All rights reserved.
- Open Access
- This is an open access article distributed under the CC BY-NC license.
Download article (PDF)
View full text (HTML)
Cite this article
TY - JOUR AU - John C. Moscona AU - Matthew N. Peters AU - Andrew V. Schally AU - Sudesh Srivastav AU - Patrice Delafontaine AU - Anand Irimpen PY - 2017 DA - 2017/07/13 TI - The effects of a growth hormone-releasing hormone antagonist and a gastrin-releasing peptide antagonist on intimal hyperplasia of the carotid artery after balloon injury in a diabetic rat model☆ JO - Artery Research SP - 56 EP - 64 VL - 19 IS - C SN - 1876-4401 UR - https://doi.org/10.1016/j.artres.2017.06.006 DO - 10.1016/j.artres.2017.06.006 ID - Moscona2017 ER -